Please login to the form below

Not currently logged in
Email:
Password:

Bicycle Therapeutics appoints Lee Kalowski

He joins the biotech from Tokai Pharmaceuticals

Lee KalowskiBiotechnology group Bicycle Therapeutics has appointed Lee Kalowski as chief financial officer at a time when the company explores a new class of therapeutics based on its proprietary bicyclic peptide product platform.

Prior to joining Bicycle, Kalowski served as the chief financial officer of Tokia Pharmaceuticals, where he helped lead the company’s $105m initial public offering in 2014.

He said: “Bicycle has pioneered a revolutionary platform that has generated a new class of drugs designed to target diseases more effectively.

“I am trilled to be joining the company as the pipeline continues to expand and as the company transitions into a clinical-stage biotech.”

Kalowski has also served Credit Suisse as its vice president, global biotechnology equity research and he has also worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson.

Kevin Lee, chief executive officer of Bicycle Therapeutics, said: “We are delighted to welcome Lee to the Bicycle team at this exciting time for our company.

“He brings a wealh of experience working with biotech companies at all stages of their evolution, both as a wall street research analyst and as a public company CFO, and his insights will prove invaluable as we continue to grow our business, expand our pipeline and move our lead candidate, BT1718, into clinical development.”

9th August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics